Artificial intelligence was more accurate in defining prostate cancer than standard of care procedures, a study from The Journal of Urology found.
The study was done at the University of California, Los Angeles and published on 1 July. It compared Avenda Health’s US Food and Drug Administration 510(k)-approved device Unfold AI (formerly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?